CohBar, Inc. (CWBR) |
2.19 0.11 (5.29%)
|
01-27 15:59 |
Open: |
2.08 |
Pre. Close: |
2.08 |
High:
|
2.21 |
Low:
|
2.05 |
Volume:
|
18,847 |
Market Cap:
|
6(M) |
|
|
Technical analysis |
as of: 2023-01-27 4:43:39 PM |
Overall:
|
|
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
Target: |
Six months: 2.79 One year: 3.26 |
Support: |
Support1: 1.84 Support2: 1.5 |
Resistance: |
Resistance1: 2.39 Resistance2: 2.79 |
Pivot: |
2.1  |
Moving Average: |
MA(5): 2.14 MA(20): 2.01 
MA(100): 2.43 MA(250): 5  |
MACD: |
MACD(12,26): 0 Signal(9): 0  |
Stochastic oscillator: |
%K(14,3): 60.1 %D(3): 62.8  |
RSI: |
RSI(14): 60.4  |
52-week: |
High: 10.52 Low: 0.17 |
Average Vol(K): |
3-Month: 30 (K) 10-Days: 27 (K) |
|
Price, moving averages and Bollinger Bands |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CWBR ] has closed below upper band by 9.3%. Bollinger Bands are 79% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend. |
|
Stock Price Prediction |
Update at 5:00pm EST |
If tomorrow:
|
Open lower
|
Open higher
|
High:
|
2.21 - 2.22 |
2.22 - 2.23 |
Low:
|
2.03 - 2.04 |
2.04 - 2.05 |
Close:
|
2.17 - 2.19 |
2.19 - 2.21 |
|
Company Description |
CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California. |
Headline News |
Wed, 25 Jan 2023 Is CohBar Inc (CWBR) Stock a Good Value Wednesday? - InvestorsObserver
Tue, 17 Jan 2023 Is CohBar Inc (CWBR) Stock a Attractive Value? - InvestorsObserver
Wed, 04 Jan 2023 CohBar Inc (CWBR) Stock Is Up 15.48% This Week: Buy, Hold, or Sell? - InvestorsObserver
Thu, 17 Nov 2022 CohBar (CWBR) retained Ladenburg Thalmann & Co. Inc. as a ... - StreetInsider.com
Wed, 26 Oct 2022 CohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022 - Yahoo Finance
Mon, 26 Sep 2022 7 Nasdaq Stocks to Sell Before They Die - InvestorPlace
|
Financial Analysis |
Price to Book Value: |
Neutral |
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Price to Earnings: |
Underperform |
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Discounted cash flow: |
Outperform |
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Return on Assets: |
Underperform |
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Return on Equity: |
Underperform |
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Debt to Equity: |
Neutral |
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
Free Technical Analysis Charts
|
|
Stock Basics & Statistics |
Exchange: NASDAQ |
Sector: Healthcare |
Industry: Biotechnology |
Shares Out. |
3 (M) |
Shares Float |
2 (M) |
% Held by Insiders
|
15 (%) |
% Held by Institutions
|
7.1 (%) |
Shares Short
|
39 (K) |
Shares Short P.Month
|
26 (K) |
Stock Financials |
EPS
|
-0.21 |
EPS Est Next Qtl
|
0 |
EPS Est This Year
|
0 |
EPS Est Next Year
|
0 |
Book Value (p.s.)
|
6.44 |
Profit Margin (%)
|
0 |
Operating Margin (%)
|
0 |
Return on Assets (ttm)
|
-39.6 |
Return on Equity (ttm)
|
-68.5 |
Qtrly Rev. Growth
|
0 |
Gross Profit (p.s.)
|
0 |
Sales Per Share
|
0 |
EBITDA (p.s.)
|
-3.83 |
Qtrly Earnings Growth
|
0 |
Operating Cash Flow
|
-10 (M) |
Levered Free Cash Flow
|
-6 (M) |
Stock Valuations |
PE Ratio
|
-10.85 |
PEG Ratio
|
0 |
Price to Book value
|
0.33 |
Price to Sales
|
0 |
Price to Cash Flow
|
-0.62 |
Stock Dividends |
Dividend
|
0 |
Forward Dividend
|
0 |
Dividend Yield
|
0% |
Dividend Pay Date
|
Invalid DateTime. |
Ex-Dividend Date
|
Invalid DateTime. |
Your Ad Here
|
|